Cafestol

CAT:
804-HY-N6257-03
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Cafestol - image 1

Cafestol

  • UNSPSC Description:

    Cafestol is an orally active diterpenoid and an inhibitor of ERK2. Cafestol has elevated blood lipids, anti-inflammatory, anti-angiogenic and anti-diabetic activities. In addition, Cafestol induces tumor cell apoptosis and autophagy, which can be used in the study of cancer[1][2][3][4].
  • Target Antigen:

    AP-1; Apoptosis; Autophagy; COX; ERK; FAK; NF-κB; PGE synthase
  • Type:

    Natural Products
  • Related Pathways:

    Apoptosis;Autophagy;Immunology/Inflammation;MAPK/ERK Pathway;NF-κB;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
  • Applications:

    COVID-19-immunoregulation
  • Field of Research:

    Cancer; Endocrinology; Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease
  • Assay Protocol:

    https://www.medchemexpress.com/cafestol.html
  • Purity:

    99.91
  • Solubility:

    DMSO : 100 mg/mL (ultrasonic)
  • Smiles:

    C[C@]12[C@@]3([H])[C@@]4(CC[C@]1([H])C5=C(OC=C5)CC2)C[C@@]([C@](CO)(O)C4)([H])CC3
  • Molecular Weight:

    316.43
  • References & Citations:

    [1]Shen T, et al. Cafestol, a coffee-specific diterpene, is a novel extracellular signal-regulated kinase inhibitor with AP-1-targeted inhibition of prostaglandin E2 production in lipopolysaccharide-activated macrophages. Biol Pharm Bull. 2010;33(1):128-32.|[2]Wang S, et al. Antiangiogenic properties of cafestol, a coffee diterpene, in human umbilical vein endothelial cells. Biochem Biophys Res Commun. 2012 May 11;421(3):567-71.|[3]Feng Y, et al. Cafestol inhibits colon cancer cell proliferation and tumor growth in xenograft mice by activating LKB1/AMPK/ULK1-dependent autophagy. J Nutr Biochem. 2024 Jul;129:109623.|[4]Mellbye FB, et al. Cafestol, a Bioactive Substance in Coffee, Has Antidiabetic Properties in KKAy Mice. J Nat Prod. 2017 Aug 25;80(8):2353-2359.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    4°C (Powder, protect from light)
  • Clinical Information:

    No Development Reported
  • CAS Number:

    469-83-0